The Osteosarcoma Biobank in Peking University People's Hospital

Osteosarcoma Clinical Trial

Official title:

Establishment of Osteosarcoma Biobank

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03362086
• Other study ID #: PKU-osteosarcoma
• Status: Not yet recruiting
• Phase: N/A
• First received: November 26, 2017
• Last updated: December 2, 2017
• Start date: February 1, 2018
• Est. completion date: February 1, 2024

Study information

• Verified date: December 2017
• Source: Peking University People's Hospital
• Contact: Kuisheng Liu, phD
• Phone: +8601088324471
• Email: liukuisheng01[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Osteosarcoma is very rare bone tumor. The investigator set up the biobank to ensure the patients has the chance to participate in future research

Description:

Samples of blood and other stored material such as slides,frozen tissues and so on .

Questionnaire information, including health history, growth and development, physical activity and family medical history information.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 180
• Est. completion date: February 1, 2024
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Proband Inclusion criteria: A diagnosis or suspected diagnosis of osteosarcoma

Exclusion Criteria:

non-asian pulmonary metastasis

Related Conditions & MeSH terms

• Osteosarcoma

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University People's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Examine VEGFR-2 and PD-L1 gene expression osteosarcoma	To examine the VEGFR2 and programmed cell death ligand 1 (PD-L1) genes expression of the patients with osteosarcoma.And Analyze their differences.	3 years